| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514566000 | Polycarboxylic acid | 23 |
| 20090030081 | USE OF LR-90 AND LR-102 TO OVERCOME INSULIN RESISTANCE - The present invention provides methods for ameliorating, overcoming, or inhibiting insulin resistance in a subject, comprising administering to the subject an effective amount of a compound selected from the group consisting of LR-90 and LR-102, or a pharmaceutically acceptable salt or derivative thereof. Methods of treating type 2 diabetes and diabetic nephropathy, or preventing or slowing their development are also encompassed by the invention. | 01-29-2009 |
| 20090149541 | Method of delaying the onset of clinically definite multiple sclerosis - A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the patient, thereby delaying onset of clinically definite multiple sclerosis in the patient and retarding long-term progression of multiple sclerosis and its symptoms. | 06-11-2009 |
| 20090170947 | DISINFECTANT COMPOSITIONS, METHODS AND SYSTEMS - Disinfectant compositions comprising PHMB and EDTA salt(s) are disclosed. The disinfectant compositions have also demonstrated activity as enhanced, fast acting catheter lock/flush solutions. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections. | 07-02-2009 |
| 20090275660 | STABLE PARENTERAL FORMULATIONS OF TIGECYCLINE - The present invention relates to stable parenteral formulations of tigecycline and process of preparation thereof, wherein the formulation comprises of an edetate, a pH modifying agent or an antioxidant, such that the formulation remains stable for at least 45 hours. | 11-05-2009 |
| 20100022652 | Antimicrobial and Anticoagulant Compositions and Methods - A composition may include a combination of at least one chelating agent and at least one antioxidant agent, the combination may have a fractional inhibitory concentration coefficient of about 0.5 or less and/or an INR of > about 2.82. | 01-28-2010 |
| 20100035992 | Methods and Compositions for Treating Inflammation and Inflammation-Related Pathologies - Methods and compositions are provided for the treatment of inflammation and disorders, diseases, and adverse conditions, i.e., pathologies, caused by or otherwise associated with inflammatory processes. A metal ion sequestering agent that directly or indirectly exerts an anti-inflammatory effect is administered to a subject in combination with a sequestration inactivating moiety that facilitates transport of the metal ion sequestering agent through biological membranes. The sequestration inactivating moiety also inactivates the metal ion sequestering agent until association between the two components is cleaved in vivo to release the active sequestering agent. Compositions containing a metal ion sequestering agent and a sequestration inactivating moiety are also provided; the compositions optionally contain an added anti-inflammatory agent. | 02-11-2010 |
| 20100063152 | Method and Topical Formulation for Treating Localized Edema - Methods and formulations are provided for the treatment of localized edema, particularly localized edema resulting from chronic venous insufficiency. A metal ion sequestrant is topically administered to a subject afflicted with localized edema in combination with a permeation enhancer selected from methylsulfonylmethane and a combination of methylsulfonylmethane and dimethylsulfoxide. Topically administrable formulations for use in the aforementioned method are also provided. | 03-11-2010 |
| 20110213035 | BIOCIDE AGENTS AGAINST MARINE WOODBORERS - The present invention relates to biodegradable biocide agents against marine woodborers. In particular, the present invention relates to novel slow releasing biocide impregnating solutions against marine woodborers, and methods of creating anti marine woodborer environments. | 09-01-2011 |
| 20110301240 | CONDITIONING COMPOSITION - The present invention is directed to a composition for the conditioning of a dental mineralized surface and/or a dental implant and/or for increasing the hydrophilicity of a dental implant having a metal containing surface. The composition comprises EDTA in a concentration of 21-55% by weight and having a pH of 9.0 or above. The high pH of the composition allows more EDTA to be dissolved and the composition is useful for the conditioning of mineralized dental surfaces and/or surfaces of dental implants. The composition of the invention may thus be used for the conditioning of mineralized dental surfaces and dental implant surfaces in order to remove e.g. biofilm, debris, bacteria, bacterial toxins etc and/or for increasing the hydrophilicity of an implant having a metallic surface. The invention is also directed to a kit comprising the composition of the invention and a device to apply the composition to a surface in need of conditioning. | 12-08-2011 |
| 20120022162 | Mixed Amino Acid/Mineral Compounds Having Improved Solubility - Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom. | 01-26-2012 |
| 20120071559 | METHODS OF QUANTIFYING N2-(1-CARBOXYETHYL)-2'-DEOXY-GUANOSINE (CEdG) AND SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING CEdG - Methods of quantifying a N | 03-22-2012 |
| 20120232151 | Process for the Preparation of Gadobenate Dimeglumine Complex in a Solid Form - The present invention discloses a process for the preparation of gadobenate dimeglumine complex in a solid form. In particular, said solid form is conveniently obtained by spray-drying a corresponding liquid suspension at a given temperature and concentration. The present invention is particularly advantageous for the industrial scale as the solid form may be obtained by employing water as a solvent, which is a non-toxic solvent, easy to handle and basically not requiring troublesome health or safety precautions. | 09-13-2012 |
| 20140024719 | Antiseptic compositions, methods and systems - Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections. | 01-23-2014 |
| 20140194518 | Antiseptic compositions, methods and systems - Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections. | 07-10-2014 |
| 20140194519 | Antiseptic compositions, methods and systems - Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections. | 07-10-2014 |
| 20140275258 | Chelation Suppository for Improved Drug Delivery - Described herein is a method of delivering drugs to the blood stream directly by absorption through cell membranes in the wall of the rectum from a rectal suppository comprising a glyceride based excipient More specifically, CaNa | 09-18-2014 |
| 20140275259 | Direct Lipid to Membrane Drug Delivery - Described herein is a method of delivering hydrophilic drugs directly from a hydrophobic carrier and/or excipient to absorbing cell membranes. More specifically, CaNa | 09-18-2014 |
| 20140275260 | Preparation Of Stable Pharmaceutical Dosage Forms - The invention provides a process for preparing stable, high API content, solid pharmaceutical dosage forms by direct compression or dry granulation, characterized in that the pharmaceutical tablets rapidly disintegrate in water or other aqueous solutions to produce a clear or almost clear solution. Also provided is a pharmaceutical carglumic acid tablet, which has improved manufacturing, dissolution, and stability properties, and is less expensive to produce, compared to the equivalent commercial product. | 09-18-2014 |
| 20150105465 | Antiseptic compositions, methods and systems - Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections. | 04-16-2015 |
| 20150290156 | METHODS OF QUANTIFYING N2-(1-CARBOXYETHYL)-2'-DEOXY-GUANOSINE (CEDG) AND SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING CEDG - Methods of quantifying a N | 10-15-2015 |
| 20160030614 | ANTISEPTIC COMPOSITIONS, METHODS AND SYSTEMS - Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections. | 02-04-2016 |
| 20160136274 | MEDICINAL COMPOSITION FOR PROMOTING SYNTHESIS OF PROTOPORPHYRIN IX - The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX. | 05-19-2016 |
| 20180021285 | METHOD FOR VISUALIZATION OF CALCIUM CONTAINING COMPONENTS IN BIOLOGICAL SYSTEMS | 01-25-2018 |
